Developer docs
API playgroundTry for free, no card

Search company profiles

Annexon Biosciences

Full company profile

uuid0003dcu

Namestring
Annexon Biosciences
Legal namestring
Annexon, Inc.
Websiteurl
annexonbio.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
complement therapeutics, classical complement pathway, C1q inhibition, neurodegenerative disease drugs, autoimmune disease therapeutics
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
Product category
Complement Therapeutics Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. No approved products yet. Revenue expected upon regulatory approval and commercialization of tanruprubart, vonaprument, and other pipeline candidates.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Tanruprubart (ANX005)
Description

Clinical-stage investigational monoclonal antibody for intravenous administration designed to inhibit C1q and the entire classical complement pathway for treatment of Guillain-Barré Syndrome (GBS).

annexonbio.com
+3 more records
Core offering1 text field

Annexon Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that inhibit C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its pipeline includes the IV monoclonal antibody Tanruprubart (ANX005) for Guillain-Barré Syndrome, the intravitreal Fab Vonaprument (ANX007) for geographic atrophy, the oral small molecule ANX1502 for complement-mediated autoimmune diseases, and the subcutaneous Fab ANX009 for antibody-mediated autoimmune diseases such as lupus nephritis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ARCHER II Phase 3 trial enrollment completed; Ph3 data expected 2H26 for vonaprument in geographic atrophy
+1 more record
Product and service4 records
1Tanruprubart (ANX005)
CategoryInvestigational therapeutic — autoimmune / neurology franchise
Description

Tanruprubart is a clinical-stage investigational monoclonal antibody (mAb) designed for intravenous administration that inhibits C1q and the entire classical complement pathway. It is being developed for the treatment of Guillain-Barré Syndrome (GBS), a severe acute neuromuscular disease caused by autoantibody attack on peripheral nerves. It has received FDA Fast Track and Orphan Drug designations and EMA Orphan Drug Designation.

2Vonaprument (ANX007)
CategoryInvestigational therapeutic — ophthalmology franchise
Description

Vonaprument is a clinical-stage investigational monoclonal antibody antigen-binding fragment (Fab) formulated for intravitreal (IVT) administration, targeting C1q and the entire classical pathway while preserving normal immune activity of the lectin and alternative complement pathways. It is being developed for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. It has received FDA Fast Track and EMA PRIME designations.

3ANX1502
CategoryInvestigational therapeutic — autoimmune franchise
Description

ANX1502 is a first-in-class oral small molecule inhibitor of the classical complement pathway being developed for complement-mediated autoimmune diseases, including cold agglutinin disease. The oral route differentiates it from the company's antibody-based programs and supports chronic dosing in autoimmune indications.

4ANX009
CategoryInvestigational therapeutic — autoimmune franchise
Description

ANX009 is a subcutaneously administered antigen-binding fragment (Fab) being developed for antibody-mediated autoimmune diseases of blood and vascular tissues, including lupus nephritis, a severe nephritic disease characterized by autoantibody-driven C1q activation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-18
Description

MindWalk Holdings Corp. released a systematic report documenting over 20 discovery-originated drug candidates their antibody discovery work produced for partners. Annexon Biosciences is listed among partner companies advancing clinical-stage programs originated through MindWalk's discovery work. MindWalk's proprietary wet-lab antibody discovery platform and HYFT biological intelligence infrastructure support Annexon's clinical programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Apellis is the most direct competitor with Syfovre (pegcetacoplan), the first FDA-approved C3 inhibitor for geographic atrophy, and Empaveli for PNH. Both companies target complement-mediated diseases with ocular and systemic programs in late-stage development.

TypeBroad incumbent
Description

Alexion pioneered complement therapeutics with Soliris and Ultomiris (C5 inhibitors) for PNH, aHUS, gMG, and NMOSD, and has commercial reach and a deep autoimmune/neurology pipeline. Annexon's C1q approach competes against Alexion's installed base in complement-mediated indications.

TypeDirect peer
Description

Iveric developed Izervay (avacincaptad pegol), a C5 inhibitor approved for geographic atrophy and acquired by Astellas in 2023. It is a direct competitor to vonaprument in the same indication, shaping market dynamics for any Annexon GA launch.

TypeDirect peer
Description

argenx developed Vyvgart (efgartigimod), an FcRn antibody approved for generalized myasthenia gravis and expanding into CIDP and other autoimmune indications. Both companies are clinical/commercial-stage antibody developers focused on antibody-mediated autoimmune diseases.

TypeBroad incumbent
Description

Regeneron is a major antibody platform company with Eylea HD for retinal disease and a deep immunology pipeline including linvoseltamab and odronextamab. It represents an incumbent competitive threat across Annexon's ophthalmology and autoimmune programs.

TypeBroad incumbent
Description

Roche/Genentech markets Ocrevus for MS and has a broad immunology and ophthalmology franchise. Annexon's MS/ALS/Huntington's programs and lupus nephritis indications compete against Roche's established autoimmune commercial footprint.

TypeBroad incumbent
Description

BioMarin is a commercial-stage rare disease biotech with multiple specialty therapeutics. Annexon's GBS, ALS, and Huntington's programs target rare neurological diseases where BioMarin's commercial and regulatory experience sets a comparable benchmark.

TypeBroad incumbent
Description

Through its Shire acquisition, Takeda has a large rare disease and neuroscience franchise including Takhzyro (HAE) and Adynovate. Annexon's complement-mediated neuro programs compete for similar specialty neurology patients and physician networks.

TypeEmerging player
Description

Alnylam develops RNAi therapeutics for rare diseases including Onpattro, Givlaari, and Oxlumo. Both companies target rare genetic and complement-mediated diseases with novel modality platforms advancing through similar commercial inflection points.

TypeEmerging player
Description

Cabaletta is a clinical-stage biotech developing CAAR T-cell therapies for autoimmune diseases including lupus nephritis and myositis. They overlap with Annexon's autoimmune disease focus, particularly in lupus nephritis where ANX009 is in development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Annexon Biosciences

Complement Therapeutics Biopharmaceuticalsannexonbio.com

Annexon Biosciences firmographics

Firmographics
Name
Annexon Biosciences
Legal name
Annexon, Inc.
Website
https://annexonbio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Annexon Biosciences industry classification

Industry
Product category
Complement Therapeutics Biopharmaceuticals
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Complement therapeutics
  • Classical complement pathway
  • C1q inhibition
  • Neurodegenerative disease drugs
  • Autoimmune disease therapeutics

Where Annexon Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Annexon Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. No approved products yet. Revenue expected upon regulatory approval and commercialization of tanruprubart, vonaprument, and other pipeline candidates.

Go-to-market motion1 record

Marketing channels3 records

Annexon Biosciences product offering

Product offering

Core offering

Annexon Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that inhibit C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its pipeline includes the IV monoclonal antibody Tanruprubart (ANX005) for Guillain-Barré Syndrome, the intravitreal Fab Vonaprument (ANX007) for geographic atrophy, the oral small molecule ANX1502 for complement-mediated autoimmune diseases, and the subcutaneous Fab ANX009 for antibody-mediated autoimmune diseases such as lupus nephritis.

Differentiator

Problem solved

Functional benefit

Brands

  • Tanruprubart (ANX005): Clinical-stage investigational monoclonal antibody for intravenous administration designed to inhibit C1q and the entire classical complement pathway for treatment of Guillain-Barré Syndrome (GBS).
  • Vonaprument (ANX007)
  • ANX1502
  • ANX009

Products and services

  • Tanruprubart (ANX005) Tanruprubart is a clinical-stage investigational monoclonal antibody (mAb) designed for intravenous administration that inhibits C1q and the entire classical complement pathway. It is being developed for the treatment of Guillain-Barré Syndrome (GBS), a severe acute neuromuscular disease caused by autoantibody attack on peripheral nerves. It has received FDA Fast Track and Orphan Drug designations and EMA Orphan Drug Designation.
  • Vonaprument (ANX007) Vonaprument is a clinical-stage investigational monoclonal antibody antigen-binding fragment (Fab) formulated for intravitreal (IVT) administration, targeting C1q and the entire classical pathway while preserving normal immune activity of the lectin and alternative complement pathways. It is being developed for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. It has received FDA Fast Track and EMA PRIME designations.
  • ANX1502 ANX1502 is a first-in-class oral small molecule inhibitor of the classical complement pathway being developed for complement-mediated autoimmune diseases, including cold agglutinin disease. The oral route differentiates it from the company's antibody-based programs and supports chronic dosing in autoimmune indications.
  • ANX009 ANX009 is a subcutaneously administered antigen-binding fragment (Fab) being developed for antibody-mediated autoimmune diseases of blood and vascular tissues, including lupus nephritis, a severe nephritic disease characterized by autoantibody-driven C1q activation.

Quantifiable outcome

  • ARCHER II Phase 3 trial enrollment completed; Ph3 data expected 2H26 for vonaprument in geographic atrophy
  • +1 more outcomes

Companies that use Annexon Biosciences

Customer profile

Segments6 records

Ideal customer profiles4 records

Annexon Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Annexon Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MindWalk Holdings Corp.coreTechnology or Integration · 18 May 2026MindWalk Holdings Corp. released a systematic report documenting over 20 discovery-originated drug candidates their antibody discovery work produced for partners. Annexon Biosciences is listed among partner companies advancing clinical-stage programs originated through MindWalk's discovery work. MindWalk's proprietary wet-lab antibody discovery platform and HYFT biological intelligence infrastructure support Annexon's clinical programs.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Annexon Biosciences competitors and assessment

Company assessment

Direct peers

  • Apellis Pharmaceuticals: Apellis is the most direct competitor with Syfovre (pegcetacoplan), the first FDA-approved C3 inhibitor for geographic atrophy, and Empaveli for PNH. Both companies target complement-mediated diseases with ocular and systemic programs in late-stage development.
  • Iveric Bio (Astellas): Iveric developed Izervay (avacincaptad pegol), a C5 inhibitor approved for geographic atrophy and acquired by Astellas in 2023. It is a direct competitor to vonaprument in the same indication, shaping market dynamics for any Annexon GA launch.
  • argenx: argenx developed Vyvgart (efgartigimod), an FcRn antibody approved for generalized myasthenia gravis and expanding into CIDP and other autoimmune indications. Both companies are clinical/commercial-stage antibody developers focused on antibody-mediated autoimmune diseases.

Broad incumbents

  • Alexion / AstraZeneca Rare Disease: Alexion pioneered complement therapeutics with Soliris and Ultomiris (C5 inhibitors) for PNH, aHUS, gMG, and NMOSD, and has commercial reach and a deep autoimmune/neurology pipeline. Annexon's C1q approach competes against Alexion's installed base in complement-mediated indications.
  • Regeneron: Regeneron is a major antibody platform company with Eylea HD for retinal disease and a deep immunology pipeline including linvoseltamab and odronextamab. It represents an incumbent competitive threat across Annexon's ophthalmology and autoimmune programs.
  • Genentech / Roche: Roche/Genentech markets Ocrevus for MS and has a broad immunology and ophthalmology franchise. Annexon's MS/ALS/Huntington's programs and lupus nephritis indications compete against Roche's established autoimmune commercial footprint.
  • BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease biotech with multiple specialty therapeutics. Annexon's GBS, ALS, and Huntington's programs target rare neurological diseases where BioMarin's commercial and regulatory experience sets a comparable benchmark.
  • Takeda Pharmaceutical: Through its Shire acquisition, Takeda has a large rare disease and neuroscience franchise including Takhzyro (HAE) and Adynovate. Annexon's complement-mediated neuro programs compete for similar specialty neurology patients and physician networks.

Emerging players

  • Alnylam Pharmaceuticals: Alnylam develops RNAi therapeutics for rare diseases including Onpattro, Givlaari, and Oxlumo. Both companies target rare genetic and complement-mediated diseases with novel modality platforms advancing through similar commercial inflection points.
  • Cabaletta Bio: Cabaletta is a clinical-stage biotech developing CAAR T-cell therapies for autoimmune diseases including lupus nephritis and myositis. They overlap with Annexon's autoimmune disease focus, particularly in lupus nephritis where ANX009 is in development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Annexon Biosciences social profiles

Digital presence

Annexon Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Annexon Biosciences leadership team

Management profile

Number of profiles

Profiles11 records

Annexon Biosciences funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Annexon Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Annexon Biosciences

What does Annexon Biosciences do?

Annexon Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that inhibit C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its pipeline includes the IV monoclonal antibody Tanruprubart (ANX005) for Guillain-Barré Syndrome, the intravitreal Fab Vonaprument (ANX007) for geographic atrophy, the oral small molecule ANX1502 for complement-mediated autoimmune diseases, and the subcutaneous Fab ANX009 for antibody-mediated autoimmune diseases such as lupus nephritis.

Is Annexon Biosciences a public or private company?

Annexon Biosciences is a public company. It is classified as public and is currently operating.

When was Annexon Biosciences founded?

Annexon Biosciences was founded in 2015. It employs 101 to 250 people.

Where is Annexon Biosciences based?

Annexon Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Annexon Biosciences make money?

One revenue line is on record: product Revenue.

Who are Annexon Biosciences's main competitors?

Direct peers on record are Apellis Pharmaceuticals, Iveric Bio (Astellas) and argenx. Broad incumbents are Alexion / AstraZeneca Rare Disease, Regeneron, Genentech / Roche, BioMarin Pharmaceutical and Takeda Pharmaceutical. Emerging players are Alnylam Pharmaceuticals and Cabaletta Bio.

Does Annexon Biosciences have an API?

No public API is recorded for Annexon Biosciences.

What industry is Annexon Biosciences in?

Annexon Biosciences's product category is Complement Therapeutics Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAnnexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)Annexon granted a new non-executive employee an option to purchase 300,000 shares of its common stock. The option has a ten-year term, an exercise price of $3.92 per share, and vests over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter.American Banking and Market NewsAnnexon, Inc. (NASDAQ:ANNX) Stock Has Consensus Price Target of $15.29Annexon's stock has a consensus price target of $15.29 with a Hold rating from ten analysts. CEO Douglas Love bought 26,065 shares at $3.83, increasing his stake by 7.15%. Analysts forecast a -1.05 EPS for the current fiscal year.American Banking and Market NewsAnnexon, Inc. $ANNX Stock Holdings Lifted by Candriam S.C.A.Candriam S.C.A. increased its Annexon stake by 40.5% in Q3, holding 1,678,986 shares worth $7.128 million. Analysts have a mixed outlook, with an average rating of Hold and a target price of $15.29. Annexon reported Q3 EPS of -$0.25, beating estimates.Seeking AlphaAnnexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy TranscriptAnnexon's CEO Douglas Love said the company is advancing toward the readout of the month 15 primary endpoint for its ARCHER II Phase III trial in geographic atrophy. The call also included clinical perspectives from retina specialists Roger Goldberg and Lloyd Clark.Stock TitanAnnexon to host Nov. 3 ARCHER II investor eventAnnexon will host a virtual investor event on November 3, 2026, to discuss its Phase 3 ARCHER II trial for geographic atrophy. The event will cover trial design, patient demographics, and communication strategy for results expected in Q4 2026, and will feature Dr. Roger Goldberg.TradingViewHC Wainwright & Co. maintains Buy rating on Annexon, $25 price targetHC Wainwright & Co. maintained a Buy rating on Annexon with a $25 price target, implying a 633% upside from the Oct 16 close of $3.41. The analyst note highlights Annexon's pipeline targeting classical complement-mediated disorders, including autoimmune and neurodegenerative diseases.MarketBeatAnnexon, Inc. (ANNX) - What Are Analysts Thinking About This Stock?Annexon's stock opened at $3.96, with analysts averaging a Hold rating and a $15.29 price target. The company missed Q2 EPS estimates at -$0.28 versus -$0.24, and CEO Douglas Love bought 26,065 shares at $3.83. Analysts predict a -1.05 EPS for the current year.Seeking AlphaAnnexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX)Annexon's lead programs for geographic atrophy and Guillain-Barré syndrome focus on preserving patient function, with ARCHER II adding a Month 24 primary assessment. The company has $209.2M in cash and expects liquidity into 2028, but faces replication risk and competition from Syfovre and Izervay.AInvestAnnexon's Inducement Grant Looks Like Routine News — the $5.29 Exercise Price Is the Real SignalAnnexon granted 287,500 stock options at $5.29 to three new hires under Nasdaq's inducement rule, with shares trading near $3.93, 26% underwater. The grant dilutes by 0.15%, and the company chose $200M debt financing over equity. Q4 2026 trials for GBS and geographic atrophy remain pending.Investing.comAnnexon at Wells Fargo 21st annual healthcare conference: late-stage push By Investing.comAnnexon outlined its late-stage pipeline at the Wells Fargo healthcare conference, highlighting vonaprument's Phase III geographic atrophy study with a dual 15- and 24-month endpoint and tanruprubart's GBS program with 90% response rates. The company is funded into 2028, with a U.S. BLA filing for GBS expected this year and a European outcome in early 2025.